1016 related articles for article (PubMed ID: 11158063)
1. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
2. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
3. Meta-[131I]iodobenzylguanidine in the scintigraphic evaluation of neural crest tumors.
Zagar I; Han R; Mitrovic S
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):13-6. PubMed ID: 9002742
[TBL] [Abstract][Full Text] [Related]
4. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors.
Lastoria S; Maurea S; Vergara E; Acampa W; Varrella P; Klain M; Muto P; Bernardy JD; Salvatore M
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):145-9. PubMed ID: 9002775
[TBL] [Abstract][Full Text] [Related]
5. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors.
Shapiro B; Sisson JC; Shulkin BL; Gross MD; Zempel S
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):3-8. PubMed ID: 9002740
[TBL] [Abstract][Full Text] [Related]
6. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors.
Limouris GS; Giannakopoulos V; Stavraka A; Toubanakis N; Vlahos L
Anticancer Res; 1997; 17(3B):1589-92. PubMed ID: 9179199
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumors and somatostatin: imaging techniques.
de Herder WW; Kwekkeboom DJ; Valkema R; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
J Endocrinol Invest; 2005; 28(11 Suppl International):132-6. PubMed ID: 16625862
[TBL] [Abstract][Full Text] [Related]
8. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Mure A; Plouin PF; Caillou B; Parmentier C
J Nucl Med; 1995 Jan; 36(1):1-6. PubMed ID: 7799058
[TBL] [Abstract][Full Text] [Related]
9. Value of 123I-MIBG Scintigraphy in Paraganglioma.
Milardovic R; Corssmit EP; Stokkel M
Neuroendocrinology; 2010; 91(1):94-100. PubMed ID: 19786729
[TBL] [Abstract][Full Text] [Related]
10. [Pre- and intraoperative localization of neuroendocrine tumors].
Adams S; Baum RP; Adams M; Wenisch H; Schumm-Draeger PM; Encke A; Usadel KH; Hör G
Acta Med Austriaca; 1997; 24(2):81-6. PubMed ID: 9273812
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor imaging for neuroendocrine tumors.
de Herder WW; Kwekkeboom DJ; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
Pituitary; 2006; 9(3):243-8. PubMed ID: 17001462
[TBL] [Abstract][Full Text] [Related]
12. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
13. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
[TBL] [Abstract][Full Text] [Related]
14. Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma.
Von Moll L; McEwan AJ; Shapiro B; Sisson JC; Gross MD; Lloyd R; Beals E; Beierwaltes WH; Thompson NW
J Nucl Med; 1987 Jun; 28(6):979-88. PubMed ID: 3035114
[TBL] [Abstract][Full Text] [Related]
15. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.
Shalaby-Rana E; Majd M; Andrich MP; Movassaghi N
Clin Nucl Med; 1997 May; 22(5):315-9. PubMed ID: 9152532
[TBL] [Abstract][Full Text] [Related]
16. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.
van der Harst E; de Herder WW; Bruining HA; Bonjer HJ; de Krijger RR; Lamberts SW; van de Meiracker AH; Boomsma F; Stijnen T; Krenning EP; Bosman FT; Kwekkeboom DJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):685-93. PubMed ID: 11158032
[TBL] [Abstract][Full Text] [Related]
17. Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors.
Pepe G; Bombardieri E; Lorenzoni A; Chiti A
PET Clin; 2014 Jan; 9(1):11-26. PubMed ID: 25029930
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeled somatostatin analog scintigraphy in medullary thyroid carcinoma and carcinoid tumor.
Rufini V; Salvatori M; Saletnich I; Valenza V; Maussier ML; Martino G; Corsello SM; Pantusa M; Casolo A; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):140-4. PubMed ID: 9002774
[TBL] [Abstract][Full Text] [Related]
19. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
Shapiro B
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
[TBL] [Abstract][Full Text] [Related]
20. MIBG and radiolabeled octreotide in neuroendocrine tumors.
Hoefnagel CA
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):137-9. PubMed ID: 9002773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
